Solid compositions of low-solubility drugs and poloxamers

1. A pharmaceutical composition comprising a mixture that is not a molecular dispersion of the following components:

(1) at least 50 wt % of particles, said particles comprising a low-solubility drug having a Log P value of greater than 6.5, and a poloxamer, wherein at least 75 wt % of said drug is amorphous; and

(2) a concentration-enhancing polymer.

2. The composition of claim 1 wherein said concentration-enhancing polymer is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, carboxymethyl ethylcellulose, and mixtures thereof.

3. The composition of claim 1 wherein component (1) is a solid solution of said drug homogeneously distributed throughout said poloxamer.

4. The composition of claim 1 or 3 wherein said mixture is a dry physical mixture.

5. The composition of claim 1 or 3 wherein components (1) and (2) of said mixture are present in different regions of said composition.

6. The composition of claim 1 wherein components (1) and (2) of said mixture are present in different layers of a multi-layer tablet.

7. The composition of claim 5 wherein said mixture is present in the same environment of use after components (1) and (2) have been co-administered to said environment of use at a time ranging from approximately the same time to within 60 minutes of each other.

8. The composition of claim 1 or 3 wherein said drug has a glass-transition temperature of at least 50° C.

9. The composition of claim 1 or 3 wherein said drug has a melting point of T m in K, and wherein said drug has a glass-transition temperature of T g,drug , in K, and wherein the ratio of said melting point to said glass transition temperature, T m /T g,drug , is less than 1.4.

10. The composition of claim 1 or 3 wherein said ratio of said melting point to said glass-transition temperature, T m /T g,drug , is less than 1.35.

11. The composition of claim 1 or 3 wherein said ratio of said melting point to said glass-transition temperature, T m /T g,drug , is less than 1.3.

12. A process for preparing a solid composition comprising the steps

(1) forming a solution consisting essentially of a low-solubility drug, a poloxamer, and a solvent; and

(2) removing said solvent from said solution to form said solid composition consisting essentially of said low-solubility drug and said poloxamer, at least a substantial portion of said drug in said composition being amorphous;

wherein said drug has a Log P value greater than 6.5.

13. The process of claim 12 wherein step (2) is selected from the group consisting of spray drying, spray coating, rotoevaporation, and evaporation.